Inhibitors of fibrin cross-linking and/or transglutaminases

Details Inhibitors of fibrin cross-linking and/or transglutaminases Inhibitors of fibrin cross-linking and/or transglutaminases

1998-05-14

2000-02-15

Woodward, Michael P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 13, 514 2, 530324, 530325, 530326, 530416, 530417, A61K 3800

Patent

active

060253304

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention is concerned with a novel class of inhibitors of fibrin cross-linking and/or of transglutaminase activity, and in particular, with such inhibitors which may be, for example, derived from leech tissue and/or from leech secretions.


BACKGROUND OF THE INVENTION

Enzymes known as transglutaminases are primarily responsible for the stabilisation of many protein aggregates, such as for example, in blood clot formation. The cross-linking of proteins by the action of transglutaminases is the major way in which, for example, fibrin clots are stabilised. In mammals, stabilisation of blood clots is brought about by a transglutaminase, known as Factor XIIIa, which catalyses the formation of cross-linking between the fibres of fibrin. Cross-linked blood clots are not as susceptible to the action of fibrinolytic enzymes and are virtually insoluble in denaturing solvents, such as 5M urea.
Factor XIIIa is an atypical coagulation enzyme since it is not a serine protease but rather a cysteine-containing, transamidating enzyme which catalyses the reaction between the amino acid side chains of lysine and glutamine to form an amide link with the elimination of ammonia according to the following scheme; ##STR1## When fibrin is the substrate, R.sub.1 --CONH.sub.2 and R.sub.2 --NH.sub.2 are glutamine and lysine side chains respectively in different chains of the fibrin polypeptide.
Factor XIIIa can also catalyse the cross-linking of other proteins. For example Factor XIIIa is known to link .alpha..sub.2 antiplasmin to fibrin and increase resistance to fibrinolysis. Moreover it can cause cross-links between a range of disparate structural and contractile proteins such as collagen, laminin actin, myosin, thrombospondin, vinculin and vitronectin or the like. It is believed that this property is part of the wound healing process and may have a role in the pathology of a number of diseases of tissue remodelling.
It is therefore desirable to provide an inhibitor of transglutaminases which inhibitor could be used, for example, in the treatnment of various pathological or thromboembolic events. Inhibitors of translutaminases have been described previously and these generally fall into four main categories: substrates;
These inhibitors are not suitable, for use in, for example, pharmaceutical formulations. for a variety of reasons, as follows:
Naturally circulating transglutaminase inhibitors have been identified previously as immunoglobulins directed at the sub-units of the transglutaminase. Such inhibitors give rise to a haemorrhagic condition caused by reduction in circulating factor XIII. U.S. Pat. No. 5,470,957 discloses using such immunoglobulins therapeutically by raising monoclonal antibodies to the transglutaminase enzyme sub-units by known techniques. A disadvantage associated with such antibodies as transglutaminase inhibitors is that they have high molecular weights and it is typically necessary to produce chimeric human analogues of the immunoglobulins before they can be used, for example, therapeutically in man.
WO91/10427 discloses transglutaminase inhibitors that are amines which act by linking to glutamine residues in one substrate to prevent cross-linking to another substrate. Such inhibitors are not very potent because they need to be present at the same concentrations as, or higher concentrations than, the natural substrate in order to have any significant inhibiting effect. Therefore they are only effective at concentrations in the region of approximately 50 .mu.M and above.
WO92/13530 discloses using various transglutaminase inhibitors which rely on the activity of transglutaminase being largely dependent on a reactive sulfhydryl group. Therefore any reagent that alkylates or oxidises this sulfhydryl group should inhibit the activity of the transglutaminase. Such reagents are, however, very reactive and also very unstable and are therefore particularly unsuitable for use in, for example, pharmaceutical or therapeutic treatment.
Attempts to provide peptidic inhibitors which migh

REFERENCES:
patent: 5114922 (1992-05-01), Maschler et al.
patent: 5227469 (1993-07-01), Lazarus et al.

Affiliated with

Also associated with

Rating

Inhibitors of fibrin cross-linking and/or transglutaminases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of fibrin cross-linking and/or transglutaminases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of fibrin cross-linking and/or transglutaminases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1905948